BaiOsaite-B (02315)' s business partner IDEAYA has obtained US Food and Drug Administration approval for IND IDE034.

Zhongtong Finance APP News, BioNTech-B (02315) announced that its partner, IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a company focused on the development of precision oncology drugs, has received approval from the U.S. Food and Drug Administration for an Investigational New Drug (IND) for the advancement of their Phase I clinical trial for the IDE034 project, a first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in the first quarter of 2026, conducting initial assessments on solid tumor types that co-express B7H3 and PTK7, including lung cancer, colorectal cancer, head and neck cancer, and ovarian/gynecological tumors.